Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A recent multidisciplinary pilot study, originating from LOMWRU and the Medicine Quality Research Group of IDDO and MORU, investigated whether bacterial, plant, fungal and animal DNA in the ingredients and from the environment (eDNA) could be detected from falsified (aka counterfeit) tablets.

Hands holding a multitude of pills © Credit Volodymyr Hryshchenko Unsplash

Collaborating scientists at Flinders University and University of Adelaide, Australia, conducted massively parallel sequencing to compare eDNA signatures between falsified and genuine antimalarials collected in Southeast Asia. They found a much greater diversity of eDNA in the falsified tablets, with differences between the diverse falsified packaging types, and also traces of human DNA.  

They coined the term ‘pharmabiome’ for the genetic signatures found in medicines and suggest that these techniques could be used to help trace the origins of falsified medicines.

This work is being expanded as part of the FORESFA Wellcome Collaborative Award to the Medicine Quality Research Group.

Read the publications 'Environmental DNA as an innovative technique to identify the origins of falsified antimalarial tablets—a pilot study of the pharmabiome' on the Nature website.

Visit the FORESFA pages on the NDM-CGHR website

Similar stories

Children with acute malnutrition and malaria: the double burden that increases risk of treatment failure

An analysis of over 11,000 falciparum malaria individual patient data sets has found that acutely malnourished children have a higher risk of reinfections and treatment failures, even when treated with recommended doses of artemisinin-based combination therapies, currently the best malaria treatment available. The malaria parasite clearance was also likely to be longer in these children.